Similarly, a paralogue-specific Hsp90 inhibitor synergizes with anti-PD1/anti-CTLA4 checkpoint inhibitor therapy in mice and results in a dramatic reduction in tumour size with a concomitant increase in survival (Rahmy et al., 2022). Here, HSP90AB1 is linked to neoplasm.